Pfizer lung cancer drug sigvotatug vedotin fails phase 3 trial

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) ...

Pfizer's lung cancer drug candidate falls short overall, shows benefit in select patients

Pfizer Inc. PFE on Monday reported mixed topline results from its Phase 3 SigVie-002 trial of investigational antibody-drug ...
BioPharma Dive

Pfizer drug acquired in Seagen deal disappoints in lung cancer study

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...
Kalkine Media

Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle?

Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...
PMLive

Pfizer announces phase 3 results for potential non-small cell lung cancer treatment

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

A CFO departure. A clinical miss. A $43 billion question mark. Should you throw in the towel on Pfizer stock?

Things are going from bad to worse for the pharmaceutical giant.
Benzinga.com

Pfizer Reports Patient Death In Marstacimab Hemophilia Extension Study

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...